Axitan has expanded its fermentation team with the appointment of Sam Romes as its new Senior Bioprocessing Engineer. Romes holds a Master’s Degree from the University of Louisville and has deep experience of manufacturing next-generation products through large-scale fermentation.
Axitan Limited, a biotech company focused on the development of endolysin enzyme products to replace antibiotics in animal feed, has announced the appointment of Sam Romes as Senior Bioprocessing Engineer. He will be responsible for managing the company’s fermentation processes and overseeing technology transfers to Contract Manufacturing Organisations as the Company builds out its global CMO network.
Al Zimmerman, CEO of Axitan, commented: “Sam brings a wealth of leading-edge, large-scale, precision fermentation experience to Axitan making him an ideal fit to the team as commercial sale volumes of our first endolysin-based product, FORC3®, continue to build.”
Sam Romes added: “It is a great honour to have joined this fast-growing business focused on the reduction and removal of antibiotics in animal feed through endolysin-based solutions.”
Endolysins are enzymes with antimicrobial activity that is specific to the pathogen being targeted and form the core of Axitan’s formulated, performance improving, feed additive products. Axitan’s first feed additive in the market, FORC3®, targets Clostridium perfringens, the pathogen that causes necrotic enteritis in poultry, according to the announcement.
Sam Romes joins Axitan from alternative food protein company EVERY where he was a Senior Bioprocess Engineer, having previously been a Bioprocess Engineer at Lawrence Berkeley National Laboratory. Romes has deep experience of manufacturing next-generation products through large-scale fermentation and managing technology transfers to Contract Manufacturing Organizations. He holds a Master’s Degree in Chemical Engineering from the University of Louisville.
